In this issue:
Chronology of mCRC
Cetuximab vs bevacizumab for KRAS wild-type
Mortality calculator for mCRC
Survival advantage with HAI for liver metastases
Aspirin use and CRC-specific survival
Survival impact of BRAF and RAS mutations
CEA and ramucirumab efficacy
Blood-based determination of RAS status
Pegfilgrastim for febrile neutropenia
Survival by site of metastatic resection
Please login below to download this issue (PDF)